With COVID-19 cases soaring across the US and worldwide, the need for a vaccine could not be greater. Here’s where we stand on vaccine development, including positive results from Pfizer’s trial.
Academic rigour, journalistic flair
Articles on AstraZeneca vaccine
Displaying 141 - 155 of 155 articles
The government has secured deals for two further COVID-19 vaccines, taking its portfolio of agreements to four.
Experts from across The Conversation look at how COVID-19 vaccines will work, how they’re being tested and manufactured, and what challenges there will be to rolling them out.
Both Moderna and AstraZeneca have used cutting-edge designs to reduce their vaccines’ development time.
With Donald Trump already doing a great job of making the public more wary of a coronavirus vaccine, big pharma has to do better than this.
Michelle Grattan discusses the political week that was with Professor Paddy Nixon
Stoppages of clinical trials are a normal part of the testing process, and show that patient safety is being taken seriously.
The phase 3 trials of the University of Oxford/AstraZeneca vaccine have been paused because one participant became unwell. But we don’t know for sure if the illness was a reaction to the vaccine.
The Australian government is working with two major pharmaceutical companies to facilitate the local production and supply of two different COVID-19 vaccines – if they’re proven to be effective.
The federal government has secured two possible vaccine sources with a $1.7 billion supply and production agreement with two pharmaceutical companies.
The vaccine hasn’t completed phase 3 trials, so we can’t be sure it will be safe and effective for all. The Australian government’s deal is contingent on these trials being successful.
Instead of a global response to the pandemic, we’re seeing an outbreak of vaccine nationalism.
The experimental vaccine stimulates the creation of antibodies. Now we need to show that these effectively protect us from the coronavirus.
The furore over US pharmaceuticals giant Pfizer’s attempted takeover of UK rival AstraZeneca continues. AstraZeneca has now rejected Pfizer’s “final” offer, as it says the proposed deal “undervalues the…
Pfizer is like Woody Allen’s famous shark. It has to keep moving or it will die. And the drug company seems unable to keep moving by any means other than acquisitions. Its all-time best-selling drug, Lipitor…
Top contributors
-
Professorial Fellow, University of Canberra
-
Senior Research Fellow in Global Health, University of Southampton
-
Professor of Medicine, University of East Anglia
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Director of the Digital Health Enterprise Zone (DHEZ), University of Bradford, Professor of Health Service Operations, University of Bradford
-
Associate Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle
-
General Practitioner, PhD Candidate, Bond University
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Chair in Epidemiology, Deakin University
-
Professor of Immunology, Vice-Chancellors Distinguished Professorial Fellow, Head of Immunology and Translational Research, Victoria University
-
Principal Lecturer, Microbiology and Biomedical Science Practice, Fellow of the Institute of Biomedical Science, University of Brighton
-
Professor of Immunology, RMIT University
-
Deputy Director of the HUMLOG (Humanitarian Logistics and Supply Chain Management Research) Institute, Hanken School of Economics
-
Professor in Clinical Pharmacy and Drug Safety, University of Birmingham
-
Associate Professor, School of Social Sciences, The University of Western Australia
